Recruiting studies: Cytokine Release Syndrome

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute
Phase 1/Phase 2 · 3 location(s) · PEACHES BIOTECH · NCT06684379 Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Phase N/A · 2 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT06339177 A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administrati
Phase 2 · 1 location(s) · Janssen Research & Development, LLC · NCT07589634 Clinical Outcomes and Inflammatory Responses in Viral vs. Bacterial Sepsis
Phase N/A · 1 location(s) · Sichuan Provincial People's Hospital · NCT06491966 Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome
EARLY_Phase 1 · 1 location(s) · University of Pennsylvania · NCT05306080 A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07106671 Early Detection of Complications During Immunotherapy for Haematological Malignancy
NA · 1 location(s) · Rigshospitalet, Denmark · NCT06377059 Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07169487 A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcita
Phase 2 · 53 location(s) · Hoffmann-La Roche · NCT06806033 Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
NA · 1 location(s) · University of Utah · NCT07390071 Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy
Phase 1/Phase 2 · 6 location(s) · CytoAgents, Inc. · NCT05905328 CytOSorb TreatMent Of Critically Ill PatientS Registry
Phase N/A · 28 location(s) · CytoSorbents, Inc · NCT05146336 Immune Modulation by Exosomes in COVID-19
Phase N/A · 1 location(s) · University of Ulm · NCT05191381 Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Phase 1 · 1 location(s) · Taylor Brooks · NCT06447376 Gluten Challenge in Celiac Disease - Which Formulation of Gluten Gives the Best Response?
NA · 2 location(s) · Oslo University Hospital · NCT07039773 Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Phase 2 · 6 location(s) · Ontario Clinical Oncology Group (OCOG) · NCT06421675 NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Phase 2/Phase 3 · 4 location(s) · Health Institutes of Turkey · NCT07502118 Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed
Phase 2 · 1 location(s) · Naresh Bumma · NCT07657312 Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Phase 2 · 17 location(s) · SCRI Development Innovations, LLC · NCT05972135 Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release S
Phase 1 · 1 location(s) · Washington University School of Medicine · NCT06008808

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.